Kute Vivek B, Hegde Umapati, Das Pratik, Sharma Ashish, Bahadur Madan M, Sil Keshab, Guleria Sandeep, Varma Prem P, Jamale Tukaram, Meshram Hari Shankar
From the Department of Nephrology, Institute of Kidney Diseases and Research Center, Dr. H. L. Trivedi Institute of Transplantation Sciences, Ahmedabad, India.
Exp Clin Transplant. 2021 Oct;19(10):1023-1031. doi: 10.6002/ect.2021.0284. Epub 2021 Sep 8.
There is scarcity of data on reoccurrence of SARS-CoV-2 infections in kidney transplant recipients.
We conducted a retrospective multicenter cohort study and identified 13 kidney transplant recipients (10 living and 3 deceased donors) with recurrent COVID-19, and here we report demographics, immunosuppression regimens, clinical profiles, treatments, and outcomes.
COVID-19 second infection rate was 0.9% (13/1350) in kidney transplant recipients with a median age of 46 years; median time interval from transplant to first episode of COVID-19 diagnosis was 9.2 months (interquartile range, 2.2-46.5 months). The most common comorbidities were hypertension (84%) and diabetes (23%). Fever was significantly less common with recurrent COVID-19. COVID-19 severity ranged from asymptomatic (23%), mild (31%), and moderate (46%) during the first infection and asymptomatic (8%), mild (46%), and severe (46%) in the second infection. All 6 kidney transplant recipients with severe second infections died. The median interval between the 2 episodes based upon reverse transcriptase polymerase chain reaction COVID-19-positive tests was 135 days (interquartile range, 71-274 days) without symptoms. Statistically significant risk factors for mortality were dyspnea (P = .04), disease severity (P = .004), allograft dysfunction (P < .05), higher levels of neutrophil-to-lymphocyte ratio (P = .05), and intensive care unit/ventilator requirement (P = .004). Although our limited resources did not allow for molecular diagnostics and typing, we suggest that these second episodes were reinfections with SARS-CoV-2.
To our knowledge, this is the largest study of kidney transplant recipients with reoccurring SARS-CoV-2 infection, and we observed 46% mortality.
关于肾移植受者中新型冠状病毒2型(SARS-CoV-2)感染复发的数据匮乏。
我们开展了一项回顾性多中心队列研究,识别出13例复发性冠状病毒病(COVID-19)的肾移植受者(10例活体供肾和3例尸体供肾),在此报告其人口统计学特征、免疫抑制方案、临床概况、治疗及结局。
肾移植受者中COVID-19二次感染率为0.9%(13/1350),中位年龄为46岁;从移植到首次COVID-19诊断的中位时间间隔为9.2个月(四分位间距,2.2 - 46.5个月)。最常见的合并症为高血压(84%)和糖尿病(23%)。复发性COVID-19时发热明显较少见。首次感染时COVID-19严重程度范围为无症状(23%)、轻症(31%)和中症(46%),二次感染时为无症状(8%)、轻症(46%)和重症(46%)。所有6例二次感染为重症的肾移植受者均死亡。基于逆转录聚合酶链反应COVID-19阳性检测的两次发作之间的中位间隔时间为135天(四分位间距,71 - 274天)且无症状。死亡的统计学显著危险因素为呼吸困难(P = 0.04)、疾病严重程度(P = 0.004)、移植肾功能障碍(P < 0.05)、较高的中性粒细胞与淋巴细胞比值水平(P = 0.05)以及重症监护病房/呼吸机需求(P = 0.004)。尽管我们有限的资源无法进行分子诊断和分型,但我们认为这些二次发作是SARS-CoV-2再感染。
据我们所知,这是关于复发性SARS-CoV-2感染的肾移植受者的最大规模研究,我们观察到死亡率为46%。